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ABSTRAK
Tujuan: untuk membandingkan kejadian kardiovaskular mayor pada penderita infark miokard akut dengan 
elevasi segmen ST (IMA-EST) yang mendapatkan terapi trombolisis dengan intervensi koroner perkutan (IKP) 
primer selama perawatan di rumah sakit. Metode: penelitian kohort retrospektif dengan melihat rekam medik 
penderita IMA-EST onset <12 jam yang dilakukan terapi trombolisis dan tindakan IKP primer di RS. Dr. 
Sardjito Yogyakarta mulai 1 Januari 2008 sampai dengan 31 Maret 2010. Luaran klinik utama adalah kejadian 
kardiovaskular mayor yaitu gabungan kematian sebab kardiovaskular, reinfark dan stroke selama perawatan 
di rumah sakit. Luaran klinik sekunder adalah angina pektoris pasca infark, gagal jantung, syok kardiogenik 
dan efek samping perdarahan. Hasil: dari 78 penderita yang mendapat terapi trombolitik dan 53 penderita 
yang dilakukan tindakan IKP primer ditemukan kejadian kardiovaskular mayor selama perawatan di rumah 
sakit tidak berbeda bermakna yaitu 10,3% vs. 9,4% (RR 1,09; 95% CI 0,33-3,55; p=0,87). Kejadian angina 
pektoris pasca infark adalah 7% vs. 3,8% (RR 2,51; 95% CI 0,50-12,60; p=0,24). Kejadian gagal jantung lebih 
tinggi dan berbeda bermakna pada terapi trombolitik (17,9% vs. 5,7%, RR 3,64; 95% CI 0,99-13,38, p=0,04) 
dengan penurunan risiko relatif 68,1% pada IKP primer. Kejadian syok kardiogenik tidak berbeda bermakna. 
Efek samping perdarahan mayor dan minor tidak berbeda bermakna. Kesimpulan: tidak ditemukan perbedaan 
bermakna kejadian kardiovaskular mayor antara IMA-EST yang diterapi trombolisis dan IKP primer selama 
perawatan rumah sakit. Kejadian gagal jantung akut lebih tinggi pada terapi trombolitik, dan IKP primer 
menurunkan risiko gagal jantung akut.
Kata kunci: kejadian kardiovaskular mayor, IMA-EST, IKP primer, trombolisis.
ABSTRACT
Aim: to compare the in-hospital major cardiovascular events between thrombolysis therapy and primary 
percutaneous coronary intervention (PCI) in patients with ST-elevation acute myocardial infarction (STEMI. 
Methods: the study design is retrospective cohort. Medical record of patients with STEMI onset <12 hour receiving 
thrombolysis treatment or primary PCI in Dr. Sardjito Hospital Yogyakarta between January 2008 and March 
2010 are evaluated. The primary outcome is major cardiovascular events which comprise cardiovascular death, 
reinfarction and stroke during hospitalisation. The secondary outcomes are post infarction angina pectoris, heart 
failure, cardiogenic shock and bleeding. Results: among 78 patients with thrombolysis and 53 patients with 
primary PCI, in-hospital major cardiovascular events do not differ significantly (10.3% versus 9.4%; RR 1.09, 
95%CI 0.33-3.55; p=0.87). Post infarction angina pectoris is 7% versus 3.8% (RR 2.51, 95%CI 0.50-12.60; 
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p=0.24). The incidence of heart failure is significantly higher in thrombolysis (17.9% versus 5.7%; RR 3.64, 
95%CI 0.99-13.38; p=0.04), primary PCI reduces 68.1% relative risk to develop acute heart failure in STEMI. 
The incidence of cardiogenic shock is not different. Major and minor bleeding do not differ significantly either. 
Conclusion: the in-hospital major cardiovascular events between STEMI receiving thrombolysis therapy and 
primary PCI is not significantly different. Heart failure is significantly higher in thrombolysis therapy and the 
primary PCI reduces the risk.
Key words: major cardiovascular events, STEMI, primary PCI, thrombolysis.
INTRODUCTION
Coronary  hear t  d iseases  current ly 
rank number one as the cause of death in 
developed countries, with acute myocardial 
infarction (AMI) as the most frequent clinical 
manifestation. In 2006, approximately 1.2 
million new cases emerged.1 Almost one third 
of AMI is diagnosed as AMI with ST segment 
elevation (STEMI). Between 25% and 35% AMI 
cases die before receiving medical treatment, 
with ventricular fibrillation as the main cause of 
death.2 The improvement of medical facilities 
and advancement of intensive managements 
have reduced the mortality rate.3 This especially 
occurs in STEMI due to the enhancement of early 
management with reperfusion strategies such as 
thrombolysis therapy or primary percutaneous 
coronary intervention (PCI).3
Thrombolysis therapy has limitations due 
to its contraindication in about 25% of cases, 
its failure in 15% and the reocclusion within 
3 months in 25% of cases. This limitations 
can be overcome by primary PCI. However, 
primary PCI requires advance facility, skilled 
human resources and longer time-frame (door 
to procedure time).4
Extensive clinical research have been 
performed comparing the effectiveness of 
thrombolysis therapy and primary PCI. Most 
studies reveal the superiority of primary PCI 
over thrombolysis therapy in the reduction of 
major adverse cardiovascular events such as 
mortality, stroke and reinfarction.5 However, the 
research mostly come from developed countries 
which pioneered the revascularisation procedures 
for STEMI. In developing countries, such as 
Indonesia, the primary PCI for STEMI is only 
recently introduced and routinely performed in 
hospitals with cath-lab facilities. Our hospital is 
one of the cardiac centers in this country which 
is capable of performing the procedure. In our 
hospital, primary PCI has been carried out 
routinely since 2008. However, no evaluation of 
the outcome has been performed yet.
In the present study, we evaluated and 
compared the in-hospital major cardiovascular 
events, i.e. the composite of death, reinfarction 
and stroke, between thrombolysis therapy and 
primary PCI in patients with STEMI onset 
<12 hour in Dr. Sardjito Hospital Yogyakarta, 
Indonesia.
METHODS
The study design was the retrospective 
cohort. The subjects were patients hospitalised 
in intensive cardiovascular care unit (ICCU) 
Dr. Sardjito Hospital with STEMI and received 
thrombolysis therapy or primary PCI. The 
medical record data of these patients were 
retrieved and evaluated from January 1, 2008 
until March 31, 2010. Inclusion criteria were 
STEMI diagnosis, anginal pain onset before 
procedure <12 hour and receiving thrombolysis 
with full dose streptokinase (1.5 million Units 
within 1 hour) or primary PCI. STEMI was 
diagnosed based on angina type chest pain 
more than 30 minutes, ST segment elevation 
on ECG with ST segment elevates >2 mmV 
in 2 consecutive precordial leads or >1 mmV 
in 2 consecutive limb leads or the new LBBB 
and dynamic elevation of creatin kinase MB 
(CK-MB) or troponin.6,7 Exclusion criteria were 
shock cardiogenic which cannot be overcome 
by primary PCI, end-stage renal disease and 
creatinin level >1.5 mg/dl. 
From the patients who satisfy the inclusion 
and exclusion criteria, we documented the 
age, gender, pain onset, time from pain onset 
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to thrombolysis therapy or primary PCI, 
history of hypertension and diabetes mellitus, 
smoking status, haemoglobin level, lipid profile, 
previous infarction, stroke, stenting or balloon 
angioplasty, CABG, history of medications, 
clinical parameters on admission, haemodynamic 
disturbance based on Killip class and infarct 
location based on ECG.
Primary outcome of the study was major 
cardiovascular events, i.e. composite of 
cardiovascular death, reinfarction and stroke, 
during intensive hospitalisation in ICCU. 
Cardiovascular death was a death due to cardial 
process such as cardiogenic shock, cardiac arrest 
or death without any other causes. Reinfarction 
was repeated anginal type chest pain and changes 
in ECG (i.e ST-segmen elevation >2 mmV in 
2 precordial leads or >1 mmV in limb leads or 
new Q wave in 2 consecutive leads and repeated 
elevation of normalized CKMB. Stroke was 
new permanent neurological deficit and/or the 
presence of cerebral hemorrhage or ischemic 
lesion. Secondary clinical outcomes are post-
infarction angina, heart failure, cardiogenic 
shock and side effects of major and minor 
bleedings.
Statistics analysis was performed with SPSS 
version 15. Patient characteristics are compared 
with T test for numerical data and chi square 
test for categorical data. Clinical outcomes 
were analysed with bivariate analysis by cross 
tabulation chi square test (95% confidence 
interval) and multiple logistic regression analysis 
for various significant confounding variables.
This study was approved by ethic committee 
of Faculty of Medicine Universitas Gadjah Mada 
Yogyakarta.
RESULTS
From medical record data, we retrieved 136 
patients with STEMI <12 hour who received 
reperfusion procedures. Thrombolysis therapy 
was performed in 80 patients, two of these 
patients are excluded because they did not 
receive full dose streptokinase. Primary PCI 
was performed in 56 patients, three of these 
patients are excluded because they suffered 
from cardiogenic shock. Of 78 patients with 
thrombolysis therapy, five patients (6.4%) have 
failed thrombolysis as indicated by no signs of 
>50% depression of ST segment within 1 hour 
after thrombolysis. Of 53 patients with primary 
PCI, forty-nine patients (92.4%) underwent stent 
placement, two patients (3.7%) had only balloon 
inflation and one patient (1.8%) had thrombus 
aspiration. Patient characteristics on admission 
and during hospitalisation in ICCU are shown 
in Table 1. The proportion of smoker, the use 
of anticoagulants and inferior wall infarction is 
significantly higher in patients with thrombolysis 
therapy. Posterior infarction is greater in patients 
receiving primary PCI. The time from admission 
to procedure (door to procedure time) is 
significantly longer in patients with primary PCI.
The proportion of in-hospital major 
cardiovascular events is not significantly different 
between patients receiving thrombolysis therapy 
and primary PCI (10.3% versus 9.4%; RR 1.09, 
95%CI 0.33-3.55; p=0.87). The proportion 
of cardiovascular death between patients 
receiving thrombolysis therapy and primary 
PCI does not significantly differ. Reinfarction 
only occurs in one patient with thrombolysis 
therapy, while stroke occurs in two patients. 
Overall, no increased risk to develop in-hospital 
major cardiovascular events are detected in 
thrombolysis group.
After adjusting using logistic regression 
analysis which included several risk factors 
which significantly differ between patients 
receiving thrombolysis therapy and primary PCI, 
i.e. smoking, the use of anticoagulant, inferior 
infarct location, posterior infarct location, total 
cholesterol level, we found that the thrombolysis 
therapy did not increase the risk for in-hospital 
major adverse cardiac events.
The incidence of post infarction angina 
pectoris is almost 4 times higher in thrombolysis 
therapy as compared with primary PCI, however 
this difference is not statistically significant. The 
incidence of heart failure is significantly higher 
in thrombolysis therapy as compared to primary 
PCI. Furthermore, primary PCI is associated with 
68.1% risk reduction of heart failure as compared 
to thrombolysis (p=0.04). The incidence of 
cardiogenic shock is not significantly different 
in thrombolysis therapy as compared to primary 
PCI (p=0.52).
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Table 1. Characteristics of patients with STEMI receiving thrombolysis therapy and primary PCI in Dr. Sardjito Hospital from 




Age (years), mean±SD 55.31±8.08 58.54±10.9
Gender, n(%)
 - Male 67(85.9) 46(86.8)
 - Female 11(14.1) 7(13.2)
Hypertension, n(%) 31(39.7) 25(47.2)
Smoking, n(%) 50(64.1) 25(47.2)
Diabetes mellitus, n(%) 19(24.4) 12(22.6)
Previous myocardial infarction, n(%) 2(2.0) 5(9.4)
Previous PCI, n(%) 0(0) 3(5.7)
Previous stroke, n(%) 3(3.8) 3(5.7)
On-admission parameters, mean±SD 
 - Systolic blood pressure (mmHg) 123.22±22.01 122.03±21.86
 - Diastolic blood pressure (mmHg) 76.15±13.7 75.05±13.89
 - Total cholesterol (mg/dl) 207.3±44.8 183.1±47.9
 - LDL cholesterol (mg/dl) 141.7±40.1 121.68±41.58
 - Random glucose (mg/dl) 184.9±113.2 168.7±58.0
In-hospital medications, n(%)
 - Aspirin 77(98.7) 53(100)
 - Clopidogrel 76(97.4) 53(100)
 - Aspirin + Clopidogrel 74(94.5) 53(100)
 - Anticoagulants 74(94.5) 35(66.1)
 - Beta blocker 20(25.6) 14(26.4)
 - Calsium channel blocker 2(2.6) 3(5.7)
 - ACE inhibitor/ARB 58(74.4) 43(81.1)
 - Diuretics 19(24.4) 15(28.3)
 - Nitrate 55(70.5) 33(62.3)
 - Statin 70(89.3) 50(94.3)
 - Insulin 20(25.6) 11(20.8)
Peak CKMB, mean±SD 137.9±88.2 125.8±123.7
Killip class, n(%)
 - I 60(76.9) 43(81.1)
 - II 10(12.8) 6(11.3)
 - III 4(5.1) 2(3.8)
 - IV 4(3.1) 2(1.5)
Infarct location, n(%)
 - Anterior 37(47.4) 27(50.9)
 - Anteroseptal 37(47.4) 27(50.9)
 - Inferior 40(51.3) 18(34.0)
 - Posterior 25(32.1) 6(11.3)
 - Lateral 16(20.5) 12(22.6)
 - Dextra 14(17.9) 5(9.11)
Pain onset (hour), mean±SD 4.4±2.4 4.8±3.9
Door to procedur time (minute), mean±SD 71.4±42.1 96.2±70.4
Irsad A. Arso                                                                                                          Acta Med Indones-Indones J Intern Med
128
Based on age, the incidence of major 
cardiovascular events among patients >60 
years old tends to be higher in those receiving 
thrombolysis therapy (23.3% versus 14.3%; RR 
1.87, 95% CI 0.38-9.12; p=0.69).
The side effect of bleeding tends to be higher 
in patients receiving thrombolysis therapy as 
compared to primary PCI. The incidence of 
major bleeding is 1.3% in thrombolysis and 
0% in primary PCI (RR 1.68, 95% 1.46-1.94; 
p=1), minor bleeding is 12.8% in thrombolysis 
and 3.8% in primary PCI (RR 3.75, 95% CI 
1.46-1.94; p=0.12) and total bleeding is 14.1% 
in thrombolysis and 3.8% in primary PCI (RR 
4.18, 95% 0.88-19.72; p=0.07).
DISCUSSION
This study showed that in-hospital major 
cardiovascular events in STEMI onset <12 hours 
did not differ significantly between patients 
receiving thrombolysis therapy and primary 
PCI. Adjusted with several confounding risk 
factors by logistic regression analysis also 
showed no significant difference. The incidence 
of cardiovascular death, reinfarction and stroke 
did not significantly differ either.
Previous studies, both clinical trials and 
cohort studies, which compared the effectiveness 
of thrombolysis therapy and primary PCI in 
STEMI showed different conclusions. Studies 
which show no significant difference between 
thrombolysis therapy and primary PCI are from 
Every et al.,8 Le May et al.,9 and Ribichini et 
al.10 In contrasts, studies reported significantly 
increased major cardiovascular events in 
thrombolysis therapy compared to primary PCI 
are studies performed by Aversano et al.11 which 
reported 16.8% versus 9.8% (p=0.03) in STEMI 
<12 hour, by Garcia et al.12 which reported 
17% versus 6.4% (p=0.01) in STEMI <5 hour, 
by GUSTO IIb trial13 which reported 13.6% 
versus 9.6% (p=0.03) incidence of 30-day major 
cardiovascular events in STEMI <12 hours and 
by Widimsky et al.14 which showed 23% versus 
8% (p=0.02) incidence of 30-day mortality in 





(n=53) RR 95% CI p value
n % n %
Major cardiovascular events 8 10.3 5 9.4 1.09 0.33-3.55 0.87
Cardiovascular death 5 6.4 4 7.5 0.83 0.21-3.28 0.80
Reinfarction 1 1.3 0 0 0.98 0.96-1.01 0.40
Stroke 2 2.6 3 5.7 0.43 0.07-2.71 0.36
Table 3. Logistic regression analysis with several risk 
factors for in-hospital major adverse cardiac events in 
patients with thrombolysis therapy as compared to patients 
receiving primary PCI
Risk factors RR 95% CI P value
Thrombolysis therapy 0.95 0.14-4.81 0.95
Smoker 1.43 0.36-5.55 0.60
Total cholesterol 
levels 0.99 0.97-1.00 0.40
Inferior infarct 0.13 0.06-1.63 0.16
Posterior infarct 1.55 0.29-8.16 0.59
Anticoagulant 
treatment 0.48 0.46-5.03 0.54
Table 4. Post infarction angina pectoris, heart failure and cardiogenic shock in STEMI patients receiving thrombolysis 





(n=53) RR 95% CI p value
n % n %
Post infarction angina 7 9.0 2 3.8 2.51 0.50-12.60 0.24
Heart failure 14 17.9 3 5.7 3.64 0.99-13.38 0.04
Cardiogenic shock 3 3.8 1 1.9 2.08 0.21-20.55 0.52
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STEMI <6 hours. Keeley et al.5 performed a 
meta-analysis from 23 clinical trials in STEMI 
<12 hours and reported cardiovascular events 
were higher in thrombolysis therapy as compared 
to primary PCI (18% versus 8%, p<0.001).
The incidence of post infarction angina 
pectoris in this study was not significantly different 
between patients receiving thrombolysis therapy 
and primary PCI. Reduction of the incidence of 
post-infarction angina pectoris by primary PCI as 
compared to thrombolysis therapy have already 
been reported.9,10,12,14 However, our study could 
not replicate the previous findings although we 
showed the tendency of risk reduction of post 
infarction angina pectoris among primary PCI.
Heart failure and cardiogenic shock 
after acute myocardial infarction are clinical 
manifestations of reduced left ventricular 
function, both systolic and diastolic functions.15 
They are derived from reduced contractile 
function in the infarcted area, infarct expansion 
and increased pressure on ventricular wall due to 
increased intraventricular blood volume. Many 
mediators and patomechanism occur in this 
vicious circle involving various organs such as 
heart, lung and kidney.16 The patency of coronary 
artery after reperfusion will improve the left 
ventricular function and heart contractility which 
halt the vicious circle.17 Therefore, successful 
reperfusion will reduce the incidence of heart 
failure and cardiogenic shock. In our study, the 
incidence of heart failure in thrombolysis patients 
is significantly higher and primary PCI reduces 
the risk of acute heart failure in about 68.1%. 
The risk of cardiogenic shock is also tended to 
decrease in primary PCI. However,the GUSTO 
IIb trial showed no significant difference of heart 
failure and cardiogenic shocks between the two 
arms.13
In this study, among elderly patients (age 
>60 years) the incidence of major cardiovascular 
events tend to be higher in thrombolysis therapy 
than in primary PCI. Primary PCI associates with 
reduced risk of 38.6% among elderly. Grines 
et al.18 investigated high-risk groups and found 
the incidence of 30-day cardiovascular events 
almost twice than low-risk groups. However, 
other study involving elderly >70 years showed 
no significant difference in major cardiovascular 
events.19
Adverse effect of bleeding, both major 
and minor bleeding, tends to be greater in 
thrombolysis. The incidence of major bleeding 
in thrombolysis therapy is 1.3%, whereas no 
bleeding is observed in primary PCI. Minor 
bleeding in thromboysis therapy is almost four-
times as compared to primary PCI, but this is not 
significant. As a whole, total bleeding is slightly 
higher by the factor of four in thrombolysis 
therapy. The result is similar with other previous 
studies.10,11,13,14
Several limitations are observed in this study. 
The first is the relatively small sample size that 
reduce the power to detect significant differences 
between groups. The second is the nature of the 
study design which involves many biases in 
the selection of patients and the allocation for 
revascularisation procedure.
CONCLUSION
The study showed no significant difference on 
the incidence of in-hospital major cardiovascular 
events in STEMI onset <12 hours between 
patients receiving thrombolysis therapy and 
primary PCI The incidence of post-infarction 
angina pectoris, cardiogenic shock and events 
among elderly tend to be higher in thrombolysis 
therapy, primary PCI reduced risk of these 
events. In-hospital heart failure was significantly 
higher in patients receiving thrombolysis therapy 
and primary PCI reduced its relative risk.
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